Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.
Read original at benzingaStocks · News reference
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 3:38 PM
- Checked
- Aug 20, 2026, 3:38 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
Read original at benzinga8-K filing — Unicycive Therapeutics, Inc. (UNCY)
Filed: 2026-08-12 AccNo: 0001213900-26-088061 Size: 279 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar